Lykos will ask FDA to reconsider its decision following rejection of MDMA therapy for post-traumatic stress disorder

Following a poor showing for Lykos Therapeutics’ MDMA candidate for post-traumatic stress disorder at a recent FDA advisory committee meeting, the other shoe has dropped.

On Friday, the FDA declined to approve Lykos’ midomafetamine (MDMA) therapy in patients with PTSD. Lykos had been seeking approval of its MDMA capsule along with psychological intervention, also known as MDMA-assisted therapy.